This study found that the AMHR2-482A>G gene polymorphism is associated with an increased likelihood of polycystic ovary syndrome and altered hormone levels in affected women.
12 citations
,
August 2011 in “European Journal of Endocrinology” This study found that anti-Müllerian hormone (AMH) is a valuable primary variable for classifying functional androgenization, especially in distinguishing ovarian-related groups, and supports the novel stratification system.
15 citations
,
September 2023 in “International Journal of Microbiology Research” This study suggests that anti-Müllerian hormone (AMH) is the most promising biomarker for diagnosing polycystic ovary syndrome (PCOS), especially in women with phenotype A and D.
4 citations
,
May 2022 in “BMC Women's Health” This study found that elevated serum AMH levels can be a strong predictor for diagnosing PCOS among women of reproductive age, when used alongside the other Rotterdam criteria.
June 2026 in “International Journal of Reproduction Contraception Obstetrics and Gynecology” This study found that serum Anti-mullerian hormone (AMH) levels are significantly elevated in women with polycystic ovary syndrome and can serve as a useful biomarker for diagnosis, especially when ultrasonography is unavailable.